AP Biosciences is an innovative antibody-based biotherapeutic developer, focusing on diseases that represent a significant burden to society, to patients, and to their families.

What We Do

Over the last 20 years, the growth of recombinant biologic therapeutic drugs, including antibodies, has had a dramatic impact on many areas of medicine, including infectious, immune-mediated, and respiratory diseases, as well as hematology and oncology. APBio is currently developing fully-human antibody-based biologics generated from our library, with novel mechanisms to fulfill unmet medical needs through proof-of-concept studies.

Combining our integrated protein engineering and antibody technology, we have produced a portfolio of biologic leads to treat serious medical conditions with a primary clinical focus on cancer, autoimmune, and inflammatory diseases. With drugs designed focusing on disease-specific targets, we aim to provide patients with medicines that are safe, efficacious and cost-effective. We believe that biotherapeutics developed this way will offer important clinical and economic advantages, making these protein drugs better choices for treatment.

What We Offer

We are open to partnering opportunities with pharmaceutical and biotech companies who are interested in working on our products, or developing new biologics for their disease targets together.




People We Have Worked With





A developer of innovative antibody-based biotherapeutics.
  • An innovative therapeutic antibody developer
  • Omni-Mab: fully-human antibody phage display library
  • Market-oriented target selection strategy
  • Mechanism-based biologic design and engineering


  • Chairperson
  • Dr. Jui-Lien Huang
  • Dr. Jui-Lien Huang is the Chairperson of AP Biosciences, Inc. Her biotechnology experience spans both the United States and Asia. Most recently, she promoted Taiwan’s biotechnology industry, by bringing two companies, AP Biosciences and Taivex, Inc., to Taiwan. Both companies’ technologies are licensed from California and developed in the Nankang Software Park in Taipei, Taiwan. Before AP Biosciences, she was Chairperson and CEO of Taivex, Inc., a company developing small molecule drugs for oncology.

    Dr. Huang was the president and CEO of the Development Center for Biotechnology (DCB), a non-profit R&D Center for pharmaceutical drug development funded by the Taiwanese Ministry of Economics (MOEA), for three and a half years. The institute also supports and promotes the Taiwanese government in developing its biotechnology industry.

    Prior to DCB, she was a co-founder, director, vice president, and Chief Operating Officer of Canji, Inc. in San Diego, CA, from 1990 to 1996. Canji was a pioneer R & D company for gene therapy and collaborated with Schering-Plough for three years before Schering-Plough’s acquisition in 1996. Prior to Canji, she worked with Vical Inc., in San Diego and Cooper Laboratory in Palo Alto, CA. Prior to the pharmaceutical industry, she conducted academic research and taught at the Department of Microbiology at the University of Texas’s medical branch in Galveston, Texas, for 7 years.

    Dr. Huang received her Ph.D. Degree at the Department of Microbiology’s Milton S. Hersey Medical School at the Pennsylvania State University, Hershey, Pa. Her post-doctoral training was from the Cancer Research Center, University of North Carolina, Chapel Hill, N.C. She also received summer Executive MBA training from the Graduate School of Business at Stanford University in Palo Alto, CA. Her bachelor’s degree was obtained from the Department of Biology from the National Taiwan Normal University in Taipei, Taiwan.

  • CEO
  • Dr. Jeng Her
  • Dr. Jeng Her, founder and CEO of AP Biosciences, is an entrepreneur in biotech industry. He received a bachelor’s degree in Physics from the National Taiwan University and a PhD in Microbiology and Immunology from the University of Virginia. Before creating AP Biosciences, he co-founded his first company, KaloBios Pharmaceuticals, in 2001 after his post-doctoral training at DNAX Research Institute. The company subsequently raised a total of $100M before it went public on NASDAQ. KaloBios was founded based on the antibody Humaneering™ technology that he co-invented to develop KaloBios’ antibody pipeline, including KB001 for ventilator-associated pneumonia, which was licensed to Sanofi-Pasteur for $290 million. The Humaneering™ technology itself was licensed out later to Novartis non-exclusively for US$30M.

    After KaloBios, Dr. Her founded ProtevoBio in Silicon Valley and continued his work on antibody therapeutics there, where he successfully developed and out-licensed an angiogenesis blocker for age-related macular degeneration (AMD) before returning to Taiwan and setting up AP Biosciences.